However, a cautionary note must be sounded following a recent report of a very rare occurrence of BRAF V600-mutant acute myeloid leukemia (AML) arising in a young child with BRAF V600 mutant LCH who had shown a CR to dabrafenib started at second relapse (following intensive chemotherapy frontline and a first relapse which manifested as hemophagocytic lymphohistiocytosis (HLH). This evidence concerns the gene BRAF and Langerhans cell histiocytosis.